Ramallah | West Bank | Healthcare | Ongoing

Strengthening PET-CT Diagnostic Imaging for Cancer Care (2025-2026)

Palestinian American medical association - PAMA

Overview

Throughout 2025, PAMA implemented a targeted intervention to stabilize PET-CT diagnostic services at the Palestine Medical Complex, ensuring uninterrupted access to advanced imaging for cancer patients across the West Bank.

The project focused on securing the continuous supply of essential radiopharmaceuticals required for PET-CT scans and upgrading diagnostic infrastructure used by radiology teams to interpret imaging results. By maintaining consistent imaging capacity and improving diagnostic tools, the initiative helped prevent service disruptions, reduce waiting times for scans, and support timely clinical decision-making for oncology care.

 

Project Details

Accurate and timely diagnostic imaging is a critical component of effective cancer care. In the West Bank, the PET-CT unit at Palestine Medical Complex (PMC) serves as the only operational public PET-CT imaging facility, providing essential diagnostic services for oncology patients referred from hospitals across the territory.

PET-CT imaging relies on specialized radiopharmaceuticals that must be delivered regularly and used within strict timeframes. Interruptions in the supply of these materials can lead to delays in cancer diagnosis, staging, and treatment planning, potentially compromising patient outcomes and increasing pressure on already limited oncology services.

Ensuring continuity of PET-CT services is therefore essential to maintaining national cancer diagnostic capacity and protecting oncology treatment pathways.

 

Objectives

The project aimed to:

  • Ensure uninterrupted PET-CT imaging services through the consistent provision of essential radiopharmaceuticals
  • Improve diagnostic accuracy by equipping radiology teams with calibrated medical-grade diagnostic monitors
  • Reduce scan waiting times and prevent delays in oncology diagnosis and treatment planning

 

Key Interventions

  • Procurement and delivery of essential radiopharmaceuticals, including FDG, required for PET-CT imaging procedures
362 units of FDG radiopharmaceuticals delivered

 

  • Strengthening diagnostic infrastructure through the provision of calibrated medical-grade monitors for accurate image interpretation
2 calibrated diagnostic display monitors for PET-CT image interpretation

 

  • Coordination with radiology and oncology teams at Palestine Medical Complex to maintain uninterrupted imaging services
2 scan cancellations recorded

 

Target Beneficiaries

The project primarily benefits cancer patients across the West Bank who require PET-CT imaging for diagnosis, staging, or treatment monitoring.

Indirect beneficiaries include oncology specialists and radiology teams relying on PET-CT diagnostics for clinical decision-making.

  • Hospitals and cancer treatment programs referring patients to the Palestine Medical Complex
  • The broader Palestinian health system, which depends on this national referral facility for advanced diagnostic imaging.

 

Service Delivery Impact

The intervention enabled the continued operation of the PET-CT unit and significantly improved access to advanced cancer diagnostics.

390 patients received PET-CT imaging services during 2025
7 days average waiting times (vs. 30+ days prior)

 

 

Share: